Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Akums invested Rs. 272 crore in capital expenditure during FY25
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Branded formulation business continues to perform well across domestic and export markets
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Subscribe To Our Newsletter & Stay Updated